DNA RNA and Cells

06 Dec 2020 Gracell Biotechnologies Announces Presentation of First-in-Human Data of GC012F a First-in-Class FasTCAR-enabled Dual-targeting BMCA/CD19 CAR-T Cell Therapy for Patients with Relapsed or Refractory Multiple Myeloma at 2020 ASH Annual Meeting
06 Dec 2020 Poseida Therapeutics Provides Update on Phase 1 Trial of P-BCMA-101 at the 2020 American Society of Hematology Annual Meeting
06 Dec 2020 Gamida Cell Presents Updated, Expanded Results from Phase 1 Study of Natural Killer Cell Therapy GDA-201 at ASH Annual Meeting and Exposition
06 Dec 2020 Preclinical Data Demonstrate Anti-Viral Activity of AlloVir’s ALVR109, an Allogeneic, Off-the-Shelf SARS-CoV-2 Specific T Cell Therapy
06 Dec 2020 Early, Deep, Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) Observed in Phase 1b/2 CARTITUDE-1 Study Show Potential of BCMA CAR-T in Treatment of Heavily Pretreated Patients with Multiple Myeloma
06 Dec 2020 Regeneron's BCMAxCD3 Bispecific Antibody (REGN5458) Shows Deep and Durable Responses in Patients with Heavily-pretreated Multiple Myeloma in Phase 1
06 Dec 2020 CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine
06 Dec 2020 Intellia Therapeutics Presents New Preclinical Data Supporting Its CRISPR/Cas9-Engineered TCR-T Cell Treatment for Acute Myeloid Leukemia at the 62nd ASH Annual Meeting
04 Dec 2020 Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R B-cell Acute Lymphoblastic Leukemia (B-ALL)
04 Dec 2020 Sirnaomics to Initiate Phase I Study of STP705 in Treatment of Primary and Metastatic Liver Cancer
04 Dec 2020 Initiation of First UniCAR Cellular Immunotherapy Study in Advanced Solid Tumors
03 Dec 2020 Janssen Acquires Rights to Novel Gene Therapy, Pioneering Treatment Solutions for Late-Stage Age-Related Macular Degeneration
02 Dec 2020 Ionis announces initiation of the global Phase 3 BALANCE study for AKCEA-APOCIII-LRX in patients with familial chylomicronemia syndrome
02 Dec 2020 Turnstone Biologics Announces First Patients Enrolled in Phase 1/2 Clinical Trial Evaluating RIVAL-01 For the Treatment of Solid Tumors
01 Dec 2020 REGENXBIO Announces Dosing of First Patient in Phase I/II Trial of RGX-111 for the Treatment of Mucopolysaccharidosis Type I
01 Dec 2020 Ionis announces AstraZeneca's initiation of the Phase 2b clinical study of its antisense medicine targeting PCSK9 to lower LDL-cholesterol
01 Dec 2020 Istari Oncology Announces First Patient Dosed in the LUMINOS-101 Phase 2 Clinical Trial of PVSRIPO in Combination with Pembrolizumab for Patients with Recurrent Glioblastoma
28 Nov 2020 DARPA and JPEO Award Contract to SmartPharm, a Subsidiary of Sorrento, for Development of Rapid Countermeasure Against COVID-19 Using Gene-Encoded Neutralizing Antibodies
25 Nov 2020 Celularity Announces Dosing of First Patient in Phase I Study of Human Placental Hematopoietic Stem Cell-Derived Natural Killer Cells (CYNK-001) in Adults with Recurrent Glioblastoma Multiforme and E-Poster Presentation at the Society for Neuro-Oncology
24 Nov 2020 Alnylam Announces U.S. Food and Drug Administration (FDA) Approval of OXLUMO™ (lumasiran), the First and Only Treatment Approved for Primary Hyperoxaluria Type 1 to Lower Urinary Oxalate Levels in Pediatric and Adult Patients
24 Nov 2020 Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development
23 Nov 2020 Catamaran Bio Launches with $42 Million Financing to Develop Off the Shelf CAR-NK Cell Therapies to Treat Solid Tumors
22 Nov 2020 DNAtrix Announces Positive Data from Phase 2 CAPTIVE (KEYNOTE-192) Study with DNX-2401 in Patients with Recurrent Glioblastoma Highlighted in an Oral Late-Breaking Presentation During Society for Neuro-oncology (SNO) Annual Meeting
20 Nov 2020 INOVIO Presents Clinical Results of its DNA Medicines INO-5401 + INO-9012 in Novel Combination with PD-1 Inhibitor Libtayo® (cemiplimab) in the Treatment of Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 2020 Annual Meeting
20 Nov 2020 Glycostem initiates phase I/IIa (pivotal) trial to evaluate the safety and efficacy of oNKord® in patients with Acute Myeloid Leukemia (AML)

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up